SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
MEDX ... anybody following?
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
2240 62 0 MEDX
Emcee:  Ed Offstein Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1965AAI-DANA FOUNDATION AWARD IN HUMAN IMMUNOLOGY RESEARCH For significant and sustaIcebrg-4/5/2008
1964Avant Gets $11.5M Payday with FDA OK of Rotarix By Catherine Hollingsworth StaffIcebrg-4/5/2008
1963As it is said, "There are many reasons to sell a stock. Anticipation of a sDennis Long-4/3/2008
1962Good or bad timing by Schaller? Charles Schaller, a director, sold 50.000 shareIcebrg-4/3/2008
1961Oh, utterly.nigel bates-4/3/2008
1960Everyone was reassured by that I'm sure.keokalani'nui-4/3/2008
1959Medarex Announces Ipilimumab Program Continues to Move Forward Thursday April 3,nigel bates-4/3/2008
1958AVANT's Single-Dose Oral Ty800 Vaccine Meets Primary Endpoints in Phase 2 StIcebrg-4/2/2008
1957Yes, it was a very disappointing result. Pfizer's trial design was most probIcebrg-4/2/2008
1956Very unfortunate. Stinks. Pfizer Announces Discontinuation of Phase III Clinickeokalani'nui-4/2/2008
1955Medarex to Receive Milestone Payment from Novo Nordisk Mar 31, 2008 06:00:00 (LJM-4/1/2008
1954MDX-1100, a fully human anti-CXCL10 (IP-10) antibody, is a high affinity, neutraIcebrg-3/30/2008
1953CXCL10-Producing Mucosal CD4(+) T Cells, NK Cells, and NKT Cells Are Associated Icebrg-3/30/2008
1952Crucell Announces STAR(R) Research License Agreement with Medarex Inc Mar 25, LJM-3/25/2008
1951Blockade of PD-1/B7-H1 Interaction Restores Effector CD8+ T Cell Responses in a Icebrg-3/21/2008
1950A high-throughput hybridoma selection method using fluorometric microvolume assaIcebrg-3/21/2008
1949>>Medarex Receives Milestone Payment for Submission of Regulatory Applicattuck-3/20/2008
1948Generation and characterization of a therapeutic human antibody to melanoma antiIcebrg-3/19/2008
1947Medarex has filed for owning 5,312,539 shares in AVANT Immunotherapeutics. AfterIcebrg-3/19/2008
1946Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals dIcebrg-3/15/2008
1945Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CIcebrg-3/14/2008
1944Medarex pecking order update. With the financials out of the way, yesterday wasIcebrg-3/5/2008
1943IMED Licenses Technology from Medarex STOCKHOLM, Sweden [Medarex poaching on GeIcebrg-3/4/2008
1942Understanding the Evolving Role of Immunotherapy in the Treatment of Malignant MIcebrg-3/1/2008
1941Medarex "underperform," target price reduced 12:20p.m. - RBC Capital MIcebrg-2/27/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News